High affinity human antibodies to tumor antigens
AssigneeThe Regents of the University of California
InventorsJames D. Marks, Robert Schier
Life of this patent
Estimating the term…
Abstract
This invention provides novel chimeric molecules that specifically binds a tumor cell bearing a c-erbB-2. The chimeric molecules comprise an effector molecule attached to a C6 antibody that specifically binds to c-erbB-2. The chimeric molecules can specifically target and deliver effector molecules to cells overexpressing c-erb-B2.
Claims25
A chimeric molecule that specifically binds a tumor cell bearing a c-erbB-2, said chimeric molecule comprising an effector molecule attached to a C6 antibody, wherein said C6 antibody comprises the variable heavy (VH) chain of C6.5 (SEQ ID NO. 32) or the variable light (VL) chain of C6.5 (SEQ ID NO. 36).
A chimeric molecule that specifically binds a tumor cell bearing a c-erbB-2, said chimeric molecule comprising an effector molecule attached to a C6 antibody, wherein said C6 antibody comprises one or more of the complementarity determining regions (CDRs) whose amino acid sequence contains a CDR sequence selected from the group consisting of the CDRs listed in Tables 4 (SEQ ID NOs. 6-24), 10 (SEQ ID NOs. 36 and 39-43), 12 (SEQ ID NOs. 44-59), 14 (SEQ ID NOs. 61 and 68-95), and 15 (SEQ ID NOs. 6, 7, 9, 12, 14, 15, 20-24, and 97-109).
A chimeric molecule that specifically binds a tumor cell bearing a c-erbB-2, said chimeric molecule comprising an effector molecule attached to a C6 antibody, wherein said C6 antibody is selected from the group consisting of an antibody having a VL domain with one of the amino acid sequences shown in Table 10, (SEQ ID NOs. 36 and 39-43) an antibody having a VH domain with one of the amino acid sequences shown in Table 12 (SEQ ID NOs. 44-59), an antibody having a VL CDR3 domain having one of the amino acid sequences shown in Tables 4 (SEQ ID NOs. 6-24) and 15 (SEQ ID NOs. 6, 7, 9, 12, 14, 15, 20-24, and 97-109), and an antibody having a VH CDR3 domain having one of the amino acid sequences shown in Table 14 (SEQ ID NOs. 61 and 68-95).
Dependencies are inferred from the claim text.